Abstract
Several factors may explain why measles persisted in the European Union in 2017–2018. The study assessed mean measles vaccination coverage and anti-measles herd immunity levels in the target measles vaccination population in countries of the European Union during the 2015–2017 period. The study found that the measles vaccination coverage with two doses of vaccine was < 95% in 28 (96.5%) countries, and that the prevalence of individuals with vaccine-induced measles protection in the target vaccination population was lower than the herd immunity threshold of 94.4% in 22 (75.9%) countries during 2015–2017. The study found a significant negative correlation between the incidence of measles in 2017–2018 in different countries of the European Union and measles vaccination coverage with two doses of measles vaccine, prevalence of individuals with vaccine-induced measles protection and herd immunity levels in the target measles vaccination population during 2015–2017. Measles vaccination coverage and herd immunity levels did not improve from 2010–2015 to 2015–2017 in the European Union. Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels could explain measles incidence in countries of the European Union in 2017–2018. New measles prevention strategies should be developed to increase measles vaccination coverage and herd immunity levels in the European Union.
Similar content being viewed by others
References
World Health Organization (WHO) (2012) Global measles and rubella strategic plan: 2012–2020. WHO, Geneva, Switzerland
Moss WJ, Strebel P (2011) Biological feasibility of measles eradication. J Infect Dis 204([supple 1]):S47–S53
World Health Organization (WHO) (2003) Strategic plan for measles and congenital rubella infection in the WHO European region. WHO Regional Office for Europe, Copenhagen, Denmark
WHO. (2015–2018) Centralized Information System for Infectious Diseases (CISID). Measles-Number of cases. Available from: http://data.euro.who.int/cisid/Default.aspx?TabID=488389. Accessed 12 Mar 2019
WHO. Centralized Information System for Infectious Diseases (CISID). Measles-Number of hospitalizations, 2015–2018. Available from: http://data.euro.who.int/cisid/?TabID=488387. Accessed 12 Mar 2019
WHO. Centralized Information System for Infectious Diseases (CISID). Measles-Number of deaths, 2015–2018. Available from: http://data.euro.who.int/cisid/?TabID=488391. Accessed 12 Mar 2019
European Centre for Disease Prevention and Control (ECDC) (2018) Monthly measles and rubella monitoring, February 2018. ECDC, Stockholm Available from: https://ecdc.europa.eu/sites/portal/files/documents/Monthly/Measles%20and%20Rubella%20monitoring%20report%20%20February%202018.pdf (Accessed 12 March 2019)
European Centre for Disease Prevention and Control (ECDC) (2019) Monthly measles and rubella monitoring report, February 2019. ECDC, Stockholm Available from: https://ecdc.europa.eu/sites/portal/files/documents/measles-rubella-monthly-monitoring-report-february-2019.pdf (Accessed 12 March 2019)
World Health Organization Regional Office for Europe (2014) Eliminating measles and rubella. Framework for the verification process in the WHO European Region. Copenhagen, WHO Regional Office for Europe. Available from: http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf
Muscat M, Bang H, Wohlfahrt J, Glismann S, Mølbak K, EUVAC.NET Group (2009) Measles in Europe: an epidemiological assessment. Lancet 373:383–389. https://doi.org/10.1016/S0140-6736(08)61849-8
European Centre for Disease Prevention and Control (ECDC) Measles: recommended vaccination. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdByDisease=-1
Plans P (2013) New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels is the population. Eur J Clin Microbiol Infect Dis 32:961–996
Anderson RM (1992) The concept of herd immunity and the design of community-based immunization programmes. Vaccine 10:928–935
Plans P, Torner N, Godoy P, Jané M (2014) Lack of herd immunity against measles in individuals aged <35 years could explain re-emergence of measles in Catalonia (Spain). Int J Infect Dis 18:81–83 Available from: http://download.journals.elsevierhealth.com/pdfs/journals/12019712/PIIS120197121300307X.pdf
Plans-Rubio P (2017) Why does measles persist in Europe? Eur J Clin Microbiol Infect Dis 36(10):1899–1906
World Health Organization (1985-2018) WHO-UNICEF estimates of MCV1 coverage [internet]. WHO, Geneva [accessed 29 January 2019]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv1.html
World Health Organization (1985-2018) WHO-UNICEF estimates of MCV2 coverage [internet]. WHO, Geneva [accessed 29 January 2019] Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv2.html
Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, Oxford, UK
Gay NJ (2003) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189(Suppl 1):S27–S35
Guerra F, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, Crowcroft NS (2017) The basic reproduction number (Ro) of measles: a systematic review. Lancet Infect Dis:e420–e428. https://doi.org/10.1016/S1473-3099(17)30307-9
Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C (2012) Vaccines for measles, mumps and rubella in children (review). The Cochrane library issue 2. Accesible from: https://www.princeton.edu/~sswang/demicheli_pietrantonj12_cochrane_report_MMR-risks.pdf
Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW (2006) Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clin Infect Dis 42:315–319. Available from: https://doi.org/10.1086/498902
Plans-Rubió P (2012) Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 8:184–188 Available from: http://www.tandfonline.com/doi/pdf/10.4161/hv.18444
McBrien J, Murphy J, Gill D, Cronin M, O’Donovan C, Cafferkey MT (2000) Measles outbreak in Dublin. Pediatr Infect Dis 22:580–584
Poland GA, Jacobson RM (2011) The age-old struggle against the antivaccinationists. Ned Engl J Med 364:97–99 Available from: http://www.edwardjennersociety.org/wp-content/uploads/NEJM.pdf
Centers for Disease Control (CDC). Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP) (2013) MMWR 62(RR04);1–34. Available from: https://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
Roberts MG, Tobias MI (2000) Predicting and preventing measles epidemics in New Zealand: application of a mathematical model. Epidemiol Infect 124:279–287
Wang B, Russell ML, Moss L, Fonseca K, Earn DJD, Aoki F et al (2016) Effect of influenza vaccination of children on infection rate in Hutterite communities: follow-up study of a randomized trial. PLoS One 11(12):e0167281. https://doi.org/10.1371/journal.pone.0167281
Burton A, Monasch R, Lautenbach B, Gacic-Dobo M, Maryanne N, Karimov R, Wolfson L, Jones G, Birmingham M (2009) WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull WHO 87:535–541. https://doi.org/10.2471/BLT.08.053819
Pannuti CS, Morello RJ, De Moraes JC, Curti SP, Afonso AMS, Camargo MCC, De Souza VAUF (2004) Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol 11:119–122
De Quadros CA, Hersh BS, Nogueira AC, Carrasco PA, da Silveira CM (1998) Measles eradication: experience in the Americas. Bull WHO 76(Suppl 2):47–52
Ion-Nedelcu N, Craciun D, Pitigoi D, Popa M, Hennessey K, Roure C, Aston R, Zimmermann G, Pelly M, Gay N, Strebel P (2001) Measles elimination: a mass immunization campaign in Romania. Am J Public Health 91:1042–1045
Acknowledgements
The average vaccination coverage for the first, the second, and two doses of measles containing vaccine in countries of the WHO European region and in the 30 countries of the European Union were calculated using the information of the WHO on “Reported estimates of MCV1 coverage”, and “Reported estimates of MCV2 coverage”:
1. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv1.html
2. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv2.html
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no conflict of interest.
Ethical approval
The work did not require an ethical approval.
Informed consent
The work did not require an informed consent.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Plans-Rubió, P. Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels explain measles incidence and persistence of measles in the European Union in 2017–2018. Eur J Clin Microbiol Infect Dis 38, 1719–1729 (2019). https://doi.org/10.1007/s10096-019-03604-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-019-03604-0